Title: Full Text of HB2346
Official Title: 
Number of Sections: 1
Source: versions - Enrolled
Media Type: text/html

================================================================================

Section 1:
Full Text of HB2346 ILGA.GOV HB2346 - 104th General Assembly HB2346 EnrolledLRB104 06540 BDA 16576 b1    AN ACT concerning health. 2    Be it enacted by the People of the State of Illinois, 3represented in the General Assembly: 4    Section 5. The Illinois Drug Reuse Opportunity Program Act 5is amended by changing Sections 5, 45, and 55 and by adding 6Section 70 as follows: 7    (410 ILCS 715/5)8    Sec. 5. Definitions. In this Act:9    "Controlled substance" means a drug, substance, or 10immediate precursor in Schedules I through V of 21 CFR 1308.11    "Department" means the Illinois Department of Public 12Health. 13    "Dispense" has the same meaning as defined in Section 3 of 14the Pharmacy Practice Act.15    "Donor" means any person, including an individual member 16of the public, or any entity legally authorized to possess 17medicine, including, but not limited to, a wholesaler or 18distributor, third party logistic provider, pharmacy, 19dispenser, clinic, surgical or health center, detention and 20rehabilitation center, jail, prison laboratory, medical or 21pharmacy school, prescriber or other health care professional, 22long-term care facility, or healthcare facility. "Donor" 23includes government agencies and entities that are federally   HB2346 Enrolled- 2 -LRB104 06540 BDA 16576 b1authorized to possess medicine, including, but not limited to, 2drug manufacturers, repackagers, relabelers, outsourcing 3facilities, health care facilities operated by the U.S. 4Department of Veterans Affairs, and prisons.5    "Drug" means a prescription drug, over-the-counter drug, 6or supplies needed to administer a prescription or 7over-the-counter drug.8    "Eligible patient" means an individual:9        (1) with a prescription for the drug, if a 10    prescription is required to dispense the drug, or who 11    reports symptoms treated by the drug if the drug is 12    over-the-counter; and13        (2) who is registered with the drug's manufacturer in 14    accordance with federal Food and Drug Administration 15    requirements, if the registration is required to dispense 16    the drug.17    "Manufacturer" has the same meaning as defined in Section 1815 of the Wholesale Drug Distribution Licensing Act.19    "Pharmacist" means an individual licensed to engage in the 20practice of pharmacy under the Pharmacy Practice Act or 21licensed to engage in the practice of pharmacy in another 22state.23    "Practitioner" means a person licensed in this State to 24dispense or administer drugs or who is licensed in another 25state as a person authorized to dispense or administer drugs.26    "Prescription drug" means any prescribed drug that may be   HB2346 Enrolled- 3 -LRB104 06540 BDA 16576 b1legally dispensed by a pharmacy. "Prescription drug" does not 2include a drug for the treatment of cancer that can only be 3dispensed to a patient registered with the drug manufacturer 4in accordance with the federal Food and Drug Administration's 5requirements.6    "Priority patient" means an eligible patient who is an 7Illinois resident and who is indigent, uninsured, 8underinsured, or enrolled in a public health benefits program.9    "Recipient" means any person or entity legally authorized 10to possess medicine with a license or permit in the state in 11which the person or entity is located, including, but not 12limited to, a wholesaler or distributor, reverse distributor, 13repackager, hospital, pharmacy, or clinic.14    "Returns processor" has the same meaning as defined in 15paragraph (18) of 21 U.S.C. 360eee. "Returns processor" 16includes, but is not limited to, a reverse distributor.17    "Unopened tamper-evident packaging" has the same meaning 18as defined in the United States Pharmacopeia (USP) General 19Chapter 659, Packaging and Storage Requirements, including, 20but not limited to, unopened unit-dose, multiple-dose, 21immediate, secondary, and tertiary packaging.22(Source: P.A. 102-389, eff. 1-1-22.) 23    (410 ILCS 715/45)24    Sec. 45. Recordkeeping requirements. When performing any 25action associated with a program under this Act or otherwise   HB2346 Enrolled- 4 -LRB104 06540 BDA 16576 b1processing a donated drug for tax, manufacturer, or other 2credit, a recipient shall be considered to be acting as a 3returns processor and shall comply with all recordkeeping 4requirements for nonsalable nonsaleable returns under federal 5law. Records maintained under this Act may be accessed by the 6Department upon request. 7(Source: P.A. 102-389, eff. 1-1-22.) 8    (410 ILCS 715/55)9    Sec. 55. Retention of records. All records required under 10this Act shall be retained in physical or electronic format 11and on or off the recipient's premises for a period of 6 years. 12Donors or recipients may contract with one another or a third 13party to create or maintain records on each other's behalf. An 14identifier, such as a serial number or bar code, may be used in 15place of any or all information required by a record or label 16pursuant to this Act if it allows for such information to be 17readily retrievable. Upon request by a State or federal 18regulatory agency, the identifier used for requested records 19shall be replaced with the original information. An identifier 20shall not be used on patient labels when dispensing or 21administering a drug. Records maintained under this Act may be 22accessed by the Department upon request. 23(Source: P.A. 102-389, eff. 1-1-22.) 24    (410 ILCS 715/70 new)  HB2346 Enrolled- 5 -LRB104 06540 BDA 16576 b1    Sec. 70. Program support provided by the Department.2    (a) The Department shall:3        (1) develop, maintain, and publish on its website 4    information regarding the names and locations of 5    pharmacies participating in the Illinois Drug Reuse 6    Opportunity Program;7        (2) educate pharmacies in the State about the Illinois 8    Drug Reuse Opportunity Program and how to participate in 9    it voluntarily;10        (3) develop and publish educational materials to allow 11    program participants and the Department to inform the 12    general public about the purposes and benefits of the 13    program; and14        (4) collect information from participants and publish 15    the information in an annual report to the General 16    Assembly by December 31 of each calendar year, beginning 17    December 31, 2026.18    (b) Pharmacy recipients shall notify the Department of 19their participation in the dispensing of drugs under this Act 20and shall report any data required in a reasonable format 21established by the Department.


================================================================================

Raw Text:
Full Text of HB2346 ILGA.GOV HB2346 - 104th General Assembly HB2346 EnrolledLRB104 06540 BDA 16576 b1    AN ACT concerning health. 2    Be it enacted by the People of the State of Illinois, 3represented in the General Assembly: 4    Section 5. The Illinois Drug Reuse Opportunity Program Act 5is amended by changing Sections 5, 45, and 55 and by adding 6Section 70 as follows: 7    (410 ILCS 715/5)8    Sec. 5. Definitions. In this Act:9    "Controlled substance" means a drug, substance, or 10immediate precursor in Schedules I through V of 21 CFR 1308.11    "Department" means the Illinois Department of Public 12Health. 13    "Dispense" has the same meaning as defined in Section 3 of 14the Pharmacy Practice Act.15    "Donor" means any person, including an individual member 16of the public, or any entity legally authorized to possess 17medicine, including, but not limited to, a wholesaler or 18distributor, third party logistic provider, pharmacy, 19dispenser, clinic, surgical or health center, detention and 20rehabilitation center, jail, prison laboratory, medical or 21pharmacy school, prescriber or other health care professional, 22long-term care facility, or healthcare facility. "Donor" 23includes government agencies and entities that are federally   HB2346 Enrolled- 2 -LRB104 06540 BDA 16576 b1authorized to possess medicine, including, but not limited to, 2drug manufacturers, repackagers, relabelers, outsourcing 3facilities, health care facilities operated by the U.S. 4Department of Veterans Affairs, and prisons.5    "Drug" means a prescription drug, over-the-counter drug, 6or supplies needed to administer a prescription or 7over-the-counter drug.8    "Eligible patient" means an individual:9        (1) with a prescription for the drug, if a 10    prescription is required to dispense the drug, or who 11    reports symptoms treated by the drug if the drug is 12    over-the-counter; and13        (2) who is registered with the drug's manufacturer in 14    accordance with federal Food and Drug Administration 15    requirements, if the registration is required to dispense 16    the drug.17    "Manufacturer" has the same meaning as defined in Section 1815 of the Wholesale Drug Distribution Licensing Act.19    "Pharmacist" means an individual licensed to engage in the 20practice of pharmacy under the Pharmacy Practice Act or 21licensed to engage in the practice of pharmacy in another 22state.23    "Practitioner" means a person licensed in this State to 24dispense or administer drugs or who is licensed in another 25state as a person authorized to dispense or administer drugs.26    "Prescription drug" means any prescribed drug that may be   HB2346 Enrolled- 3 -LRB104 06540 BDA 16576 b1legally dispensed by a pharmacy. "Prescription drug" does not 2include a drug for the treatment of cancer that can only be 3dispensed to a patient registered with the drug manufacturer 4in accordance with the federal Food and Drug Administration's 5requirements.6    "Priority patient" means an eligible patient who is an 7Illinois resident and who is indigent, uninsured, 8underinsured, or enrolled in a public health benefits program.9    "Recipient" means any person or entity legally authorized 10to possess medicine with a license or permit in the state in 11which the person or entity is located, including, but not 12limited to, a wholesaler or distributor, reverse distributor, 13repackager, hospital, pharmacy, or clinic.14    "Returns processor" has the same meaning as defined in 15paragraph (18) of 21 U.S.C. 360eee. "Returns processor" 16includes, but is not limited to, a reverse distributor.17    "Unopened tamper-evident packaging" has the same meaning 18as defined in the United States Pharmacopeia (USP) General 19Chapter 659, Packaging and Storage Requirements, including, 20but not limited to, unopened unit-dose, multiple-dose, 21immediate, secondary, and tertiary packaging.22(Source: P.A. 102-389, eff. 1-1-22.) 23    (410 ILCS 715/45)24    Sec. 45. Recordkeeping requirements. When performing any 25action associated with a program under this Act or otherwise   HB2346 Enrolled- 4 -LRB104 06540 BDA 16576 b1processing a donated drug for tax, manufacturer, or other 2credit, a recipient shall be considered to be acting as a 3returns processor and shall comply with all recordkeeping 4requirements for nonsalable nonsaleable returns under federal 5law. Records maintained under this Act may be accessed by the 6Department upon request. 7(Source: P.A. 102-389, eff. 1-1-22.) 8    (410 ILCS 715/55)9    Sec. 55. Retention of records. All records required under 10this Act shall be retained in physical or electronic format 11and on or off the recipient's premises for a period of 6 years. 12Donors or recipients may contract with one another or a third 13party to create or maintain records on each other's behalf. An 14identifier, such as a serial number or bar code, may be used in 15place of any or all information required by a record or label 16pursuant to this Act if it allows for such information to be 17readily retrievable. Upon request by a State or federal 18regulatory agency, the identifier used for requested records 19shall be replaced with the original information. An identifier 20shall not be used on patient labels when dispensing or 21administering a drug. Records maintained under this Act may be 22accessed by the Department upon request. 23(Source: P.A. 102-389, eff. 1-1-22.) 24    (410 ILCS 715/70 new)  HB2346 Enrolled- 5 -LRB104 06540 BDA 16576 b1    Sec. 70. Program support provided by the Department.2    (a) The Department shall:3        (1) develop, maintain, and publish on its website 4    information regarding the names and locations of 5    pharmacies participating in the Illinois Drug Reuse 6    Opportunity Program;7        (2) educate pharmacies in the State about the Illinois 8    Drug Reuse Opportunity Program and how to participate in 9    it voluntarily;10        (3) develop and publish educational materials to allow 11    program participants and the Department to inform the 12    general public about the purposes and benefits of the 13    program; and14        (4) collect information from participants and publish 15    the information in an annual report to the General 16    Assembly by December 31 of each calendar year, beginning 17    December 31, 2026.18    (b) Pharmacy recipients shall notify the Department of 19their participation in the dispensing of drugs under this Act 20and shall report any data required in a reasonable format 21established by the Department.